secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007665
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients
--------------------------------------------------------------------------------

- Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.
- Operating loss $4.1M (Q1 2025) vs $3.1M (Q1 2024); R&D spending up $0.9M on APR-1051 and ATRN-119 trials.
- ATRN-119 ABOYA-119 trial: 3 patients at 550mg BID had tumor shrinkage of 7%, 14%, and 21% below RP2D.
- APR-1051 ACESOT-1051 trial enrolling at 100mg QD; next cohort 150mg; preliminary efficacy data expected H2 2025.
- Entered Material Transfer Agreement with MD Anderson to study APR-1051 in head and neck cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/0001558370-25-007665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/apre-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer